Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus

PLoS Pathogens

Volumn 13, Issue 8, 2017, Pages

  Bootz, Anna ^a   Karbach, Astrid ^a   Spindler, Johannes ^a   Kropff, Barbara ^a   Reuter, Nina ^a   Sticht, Heinrich ^a   Winkler, Thomas H ^b   Britt, William J ^c   Mach, Michael ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN B; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2A; LUCIFERASE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; GLYCOPROTEIN B, SIMPLEXVIRUS; VIRUS ENVELOPE PROTEIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CHROMATOGRAPHY; CRYSTAL STRUCTURE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE; LUCIFERASE ASSAY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; VIRAL PLAQUE ASSAY; VIRUS IMMUNITY; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS TRANSMISSION; ANIMAL; DISEASE MODEL; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; DISEASE MODELS, ANIMAL; MICE; REAL-TIME POLYMERASE CHAIN REACTION; VIRAL ENVELOPE PROTEINS;

EID: 85028632954     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006601     Document Type: Article

References (69)

1. Kenneson A, Cannon MJ, Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Reviews in Medical Virology. 2007. pp. 253–276. doi: 10.1002/rmv.535 17579921
2. Ludwig A, Hengel H, Epidemiological impact and disease burden of congenital cytomegalovirus infection in Europe. Euro Surveill Bull Eur sur les Mal Transm = Eur Commun Dis Bull. 2009;14: 26–32.
3. Dreher AM, Arora N, Fowler KB, Novak Z, Britt WJ, Boppana SB, et al. Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr. 2014;164: 855–859. doi: 10.1016/j.jpeds.2013.12.007 24433826
4. Ramanan P, Razonable RR, Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother. 2013;45: 260–71. doi: 10.3947/ic.2013.45.3.260 24396627
5. Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: A CIBMTR analysis. Blood. 2016;127: 2427–2438. doi: 10.1182/blood-2015-11-679639 26884374
6. Khairallah C, Netzer S, Villacreces A, Juzan M, Rousseau B, Dulanto S, et al.???? T Cells Confer Protection against Murine Cytomegalovirus (MCMV). PLoS Pathog. 2015;11: 1–22. doi: 10.1371/journal.ppat.1004702 25747674
7. Leruez-Ville M, Ville Y, Optimum treatment of congenital cytomegalovirus infection. Expert Rev Anti Infect Ther. 2016;14: 479–488. doi: 10.1586/14787210.2016.1173540 27043943
8. Plotkin S, The history of vaccination against cytomegalovirus. Medical Microbiology and Immunology. 2015. pp. 247–254. doi: 10.1007/s00430-015-0388-z 25791890
9. Plotkin SA, Correlates of protection induced by vaccination. Clinical and Vaccine Immunology. 2010. pp. 1055–1065. doi: 10.1128/CVI.00131-10 20463105
10. Mach M, Wiegers AK, Spindler N WT, Reddehase MJ, Cytomegaloviruses. In: Caister Academic Press; 2013. pp. 215–231.
11. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol. 2010;84: 1005–1013. doi: 10.1128/JVI.01809-09 19889756
12. Zydek M, Petitt M, Fang-Hoover J, Adler B, Kauvar LM, Pereira L, et al. HCMV infection of human trophoblast progenitor cells of the placenta is neutralized by a human monoclonal antibody to glycoprotein B and not by antibodies to the pentamer complex. Viruses. 2014;6: 1346–1364. doi: 10.3390/v6031346 24651029
13. Chiuppesi F, Wussow F, Johnson E, Bian C, Zhuo M, Rajakumar A, et al. Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection. J Virol. 2015;89. doi: 10.1128/JVI.01701-15 26378171
14. Kabanova A, Perez L, Lilleri D, Marcandalli J, Agatic G, Becattini S, et al. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci U S A. 2014;111. doi: 10.1073/pnas.1415310111 25453106
15. Wussow F, Chiuppesi F, Martinez J, Campo J, Johnson E, Flechsig C, et al. Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer Complex. PLoS Pathog. 2014;10. doi: 10.1371/journal.ppat.1004524 25412505
16. Cooper RS, Heldwein EE, Herpesvirus gB: A finely tuned fusion machine. Viruses. 2015. pp. 6552–6569. doi: 10.3390/v7122957 26690469
17. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang M-L, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009;360: 1191–9. doi: 10.1056/NEJMoa0804749 19297572
18. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial. Lancet. 2011;377: 1256–1263. doi: 10.1016/S0140-6736(11)60136-0 21481708
19. Abel K, Martinez J, Yue Y, Lacey SF, Wang Z, Strelow L, et al. Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. J Virol. 2011;85: 2878–90. doi: 10.1128/JVI.00883-10 21191005
20. Shanley JD, Wu CA, Mucosal immunization with a replication-deficient adenovirus vector expressing murine cytomegalovirus glycoprotein B induces mucosal and systemic immunity. Vaccine. 2003;21: 2632–2642. doi: 10.1016/S0264-410X(03)00037-9 12744900
21. Cardin RD, Bravo FJ, Pullum DA, Orlinger K, Watson EM, Aspoeck A, et al. Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection. Vaccine. Elsevier Ltd; 2016;34: 1993–1999. doi: 10.1016/j.vaccine.2016.03.005 26973071
22. Schleiss MR, Choi KY, Anderson J, Mash JG, Wettendorff M, Mossman S, et al. Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model. Vaccine. 2014;32: 2756–2762. doi: 10.1016/j.vaccine.2013.07.010 23867012
23. Chatterjee a, Harrison CJ, Britt WJ, Bewtra C, Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. J Infect Dis. 2001;183: 1547–1553. doi: 10.1086/320714 11343203
24. Bernstein DI, Munoz FM, Callahan ST, Rupp R, Wootton SH, Edwards KM, et al. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial. Vaccine. Elsevier Ltd; 2016;34: 313–319. doi: 10.1016/j.vaccine.2015.11.056 26657184
25. Pass RF, Duliegè AM, Boppana S, Sekulovich R, Percell S, Britt W, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis. 1999;180: 970–975. doi: 10.1086/315022 10479120
26. Araullo-Cruz TP, Ho M, Armstrong JA, Protective effect of early serum from mice after cytomegalovirus infection. Infect Immun. 1978;21: 840–842. 213389
27. Shanley JD, Colin Jordan M, Stevens JG, Shanley JD, Modification by adoptive humoral immunity of murine cytomegalovirus infection. J Infect Dis. 1981;143: 231–237. doi: 10.1093/infdis/143.2.231 6260872
28. Farrell HE, Shellam GR, Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J Gen Virol. 1991;72: 149–156. doi: 10.1099/0022-1317-72-1-149 1846643
29. Jonjić S, Pavić I, Polić B, Crnković I, Lucin P, Koszinowski UH, Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med. 1994;179: 1713–7. doi: 10.1084/jem.179.5.1713 8163949
30. Cekinović D, Golemac M, Pugel EP, Tomac J, Cicin-Sain L, Slavuljica I, et al. Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. J Virol. 2008;82: 12172–80. doi: 10.1128/JVI.01214-08 18842707
31. Klenovsek K, Weisel F, Schneider A, Appelt U, Jonjic S, Messerle M, et al. Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood. 2007;110: 3472–3479. doi: 10.1182/blood-2007-06-095414 17656648
32. Pötzsch S, Spindler N, Wiegers A-K, Fisch T, Rücker P, Sticht H, et al. B Cell Repertoire Analysis Identifies New Antigenic Domains on Glycoprotein B of Human Cytomegalovirus which Are Target of Neutralizing Antibodies. PLoS Pathog. 2011;7: e1002172. doi: 10.1371/journal.ppat.1002172 21852946
33. Masuho Y, Matsumoto Y, Sugano T, Fujinaga S, Minamishima Y, Human monoclonal antibodies neutralizing human cytomegalovirus. J Gen Virol. 1987;68 (Pt 5): 1457–1461. doi: 10.1099/0022-1317-68-5-1457 2437245
34. Wiegers A-K, Sticht H, Winkler TH, Britt WJ, Mach M, Identification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus. J Virol. 2015;89: 361–72. doi: 10.1128/JVI.02393-14 25320309
35. Spindler N, Rücker P, Pötzsch S, Diestel U, Sticht H, Martin-Parras L, et al. Characterization of a discontinuous neutralizing epitope on glycoprotein B of human cytomegalovirus. J Virol. 2013;87: 8927–39. doi: 10.1128/JVI.00434-13 23740990
36. Burke HG, Heldwein EE, Crystal Structure of the Human Cytomegalovirus Glycoprotein B. PLoS Pathog. 2015;11. doi: 10.1371/journal.ppat.1005227 26484870
37. Messerle M, Crnkovic I, Hammerschmidt W, Ziegler H, Koszinowski UH, Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A. 1997;94: 14759–63. doi: 10.1073/pnas.94.26.14759 9405686
38. Jordan S, Krause J, Prager A, Mitrovic M, Jonjic S, Koszinowski UH, et al. Virus progeny of murine cytomegalovirus bacterial artificial chromosome pSM3fr show reduced growth in salivary Glands due to a fixed mutation of MCK-2. J Virol. 2011;85: 10346–53. doi: 10.1128/JVI.00545-11 21813614
39. Mathys S, Schroeder T, Ellwart J, Koszinowski UH, Messerle M, Just U, Dendritic cells under influence of mouse cytomegalovirus have a physiologic dual role: to initiate and to restrict T cell activation. J Infect Dis. 2003;187: 988–99. doi: 10.1086/368094 12660946
40. Wagner FM, Brizic I, Prager A, Trsan T, Arapovic M, Lemmermann NAW, et al. The Viral Chemokine MCK-2 of Murine Cytomegalovirus Promotes Infection as Part of a gH/gL/MCK-2 Complex. PLoS Pathog. 2013;9. doi: 10.1371/journal.ppat.1003493 23935483
41. Noda S, Aguirre SA, Bitmansour A, Brown JM, Sparer TE, Huang J, et al. Cytomegalovirus MCK-2 controls mobilization and recruitment of myeloid progenitor cells to facilitate dissemination. Blood. 2006;107: 30–38. doi: 10.1182/blood-2005-05-1833 16046529
42. Daley-Bauer LP, Roback LJ, Wynn GM, Mocarski ES, Cytomegalovirus hijacks CX3CR1hi patrolling monocytes as immune-privileged vehicles for dissemination in mice. Cell Host Microbe. 2014;15: 351–362. doi: 10.1016/j.chom.2014.02.002 24629341
43. Spindler N, Diestel U, Stump JD, Wiegers A-K, Winkler TH, Sticht H, et al. Structural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibody. PLoS Pathog. 2014;10: e1004377. doi: 10.1371/journal.ppat.1004377 25299639
44. Lavoie PM, Solimano A, Taylor R, Kwan E, Claydon J, Turvey SE, et al. Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab. JAMA Pediatr. 2016;170: 174–176. doi: 10.1001/jamapediatrics.2015.3235 26720836
45. Caskey M, Klein F, Lorenzi JCC, Seaman MS, West AP, Buckley N, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522: 487–491. doi: 10.1038/nature14411 25855300
46. Bubić I, Wagner M, Krmpotić A, Saulig T, Kim S, Yokoyama WM, et al. Gain of virulence caused by loss of a gene in murine cytomegalovirus. J Virol. 2004;78: 7536–44. doi: 10.1128/JVI.78.14.7536-7544.2004 15220428
47. Campbell AE, Cavanaugh VJ, Slater JS, The salivary glands as a privileged site of cytomegalovirus immune evasion and persistence. Medical Microbiology and Immunology. 2008. pp. 205–213. doi: 10.1007/s00430-008-0077-2 18259775
48. Collins TM, Quirk MR, Jordan MC, Biphasic viremia and viral gene expression in leukocytes during acute cytomegalovirus infection of mice. J Virol. 1994;68: 6305–11. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=237051&tool=pmcentrez&rendertype=abstract 8083970
49. Correia IR, Stability of IgG isotypes in serum. mAbs. 2010. pp. 221–232. doi: 10.4161/mabs.2.3.11788 20404539
50. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 2012;492: 118–22. doi: 10.1038/nature11604 23103874
51. Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA, Nonneutralizing functional antibodies: A new “old” paradigm for HIV vaccines. Clinical and Vaccine Immunology. 2014. pp. 1023–1036. doi: 10.1128/CVI.00230-14 24920599
52. Henry Dunand CJ, Leon PE, Huang M, Choi A, Chromikova V, Ho IY, et al. Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host Microbe. 2016;19: 800–813. doi: 10.1016/j.chom.2016.05.014 27281570
53. Schmaljohn AL, Protective Antiviral Antibodies that Lack Neutralizing Activity: Precedents and Evolution of Concepts. Curr Hiv Res. 2013;11: 345–353. doi: 10.2174/1570162X113116660057 24191933
54. Nimmerjahn F, Gordan S, Lux A, Fc??R dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends in Immunology. 2015. pp. 325–336. doi: 10.1016/j.it.2015.04.005 25981969
55. Nimmerjahn F, Ravetch J V, Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 2005;310: 1510–2. doi: 10.1126/science.1118948 16322460
56. Corrales-Aguilar E, Hoffmann K, Hengel H, CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity. Semin Immunopathol. 2014;36: 627–640. doi: 10.1007/s00281-014-0448-2 25288477
57. Vidarsson G, Dekkers G, Rispens T, IgG subclasses and allotypes: From structure to effector functions. Front Immunol. 2014;5. doi: 10.3389/fimmu.2014.00520 25368619
58. Nomura M, Kurita-Taniguchi M, Kondo K, Inoue N, Matsumoto M, Yamanishi K, et al. Mechanism of host cell protection from complement in murine cytomegalovirus (CMV) infection: Identification of a CMV-responsive element in the CD46 promoter region. Eur J Immunol. 2002;32: 2954–2964. doi: 10.1002/1521-4141(2002010)32:10<2954::AID-IMMU2954>3.0.CO;2-2 12355449
59. Spiller OB, Hanna SM, Devine D V, Tufaro F, Neutralization of Cytomegalovirus Virions: The Role of Complement. J Infect Dis. 1997;176: 339–347. 9237698
60. Sattentau Q, Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol. 2008;6: 815–826. doi: 10.1038/nrmicro1972 18923409
61. Digel M, Sampaio KL, Jahn G, Sinzger C, Evidence for direct transfer of cytoplasmic material from infected to uninfected cells during cell-associated spread of human cytomegalovirus. J Clin Virol. 2006;37: 10–20. doi: 10.1016/j.jcv.2006.05.007 16815742
62. Silva MC, Schröer J, Shenk T, Human cytomegalovirus cell-to-cell spread in the absence of an essential assembly protein. Proc Natl Acad Sci U S A. 2005;102: 2081–6. doi: 10.1073/pnas.0409597102 15684067
63. Hsu KM, Pratt JR, Akers WJ, Achilefu SI, Yokoyama WM, Murine cytomegalovirus displays selective infection of cells within hours after systemic administration. J Gen Virol. 2009;90: 33–43. doi: 10.1099/vir.0.006668-0 19088270
64. Bernstein DI, Munoz FM, Callahan ST, Rupp R, Wootton SH, Edwards KM, et al. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial. Vaccine. 2016;34: 313–319. doi: 10.1016/j.vaccine.2015.11.056 26657184
65. Zeev-Ben-Mordehai T, Vasishtan D, Hernández Durán A, Vollmer B, White P, Prasad Pandurangan A, et al. Two distinct trimeric conformations of natively membrane-anchored full-length herpes simplex virus 1 glycoprotein B. Proc Natl Acad Sci U S A. 2016;113. doi: 10.1073/pnas.1523234113 27035968
66. Renzette N, Pokalyuk C, Gibson L, Bhattacharjee B, Schleiss MR, Hamprecht K, et al. Limits and patterns of cytomegalovirus genomic diversity in humans. Proc Natl Acad Sci. 2015;112: E4120–E4128. doi: 10.1073/pnas.1501880112 26150505
67. Kropff B, Koedel Y, Britt W, Mach M, Optimal replication of human cytomegalovirus correlates with endocytosis of glycoprotein gpUL132. J Virol. 2010;84: 7039–52. doi: 10.1128/JVI.01644-09 20444903
68. Webb B, Sali A, Comparative protein structure modeling using MODELLER. Curr Protoc Bioinforma. 2014;2014: 1–32. doi: 10.1002/0471250953.bi0506s47
69. Humphrey W, Dalke A, Schulten K, VMD: Visual molecular dynamics. J Mol Graph. 1996;14: 33–38. doi: 10.1016/0263-7855(96)00018-5 8744570